SciClone Pharmaceuticals to Present at Two Investor Conferences in September

FOSTER CITY, CA, Sep 01 (MARKET WIRE) --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it
will present at two upcoming investor conferences: Rodman & Renshaw
Global Investment Conference, and UBS Global Life Sciences Conference.
SciClone's executives will present a corporate overview and business
update at each conference.

Rodman & Renshaw Global Investment Conference
Monday, September 12;
10:50 am ET (Healthcare track)
Tuesday, September 13; 9:35 am ET (China
track)
New York City, NY
Presenter: Friedhelm Blobel, PhD, President
and CEO

UBS Global Life Sciences Conference
Wednesday, September 21; 8:00 am ET

New York City, NY
Presenter: Gary Titus, Senior Vice President and CFO

To access the live audio webcasts of the presentations, please log on
through a link located in the Investor Relations section of SciClone's
website at www.sciclone.com.

About SciClone
SciClone Pharmaceuticals is a revenue-generating,
profitable, China-centric specialty pharmaceutical company with a
substantial commercial business and a product portfolio of therapies for
oncology, infectious diseases and cardiovascular, urological,
respiratory, and central nervous system disorders. SciClone's ZADAXIN(R)
(thymalfasin) is approved in over 30 countries and may be used for the
treatment of hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant,
and certain cancers according to the approvals we have in these
countries. SciClone markets nearly 20, mostly partnered products in China
besides ZADAXIN, including Depakine(R), the most widely prescribed
broad-spectrum anti-convulsant in China; Tritace(R), an ACE inhibitor for
the treatment of hypertension; Stilnox(R), a fast-acting hypnotic for the
short-term treatment of insomnia (marketed as Ambien(R) in the US); and
Aggrastat(R), a recently-launched intervention cardiology product. On the
development side, SciClone is evaluating SCV-07 in a phase 2b trial for
the delay to onset of oral mucositis in patients with head and neck
cancer. SciClone is also pursuing the registration of several other
therapeutic products in China. SciClone is headquartered in Foster City,
California. For additional information, please visit www.sciclone.com.

Ambien, Depakine, Stilnox and Tritace are registered trademarks of Sanofi
S.A.

Aggrastat is a registered trademark of Merck & Co., Inc.

Contact
Ana Kapor
Investors/Media
650.350.4825
akapor@sciclone.com

Copyright 2011, Market Wire, All rights reserved.

-0-